Vol. 6, Issue 1, Part A (2024)

Objective: To gain a comprehensive understanding of the prescription practices of teneligliptin in Indian healthcare settings. 
Methodology: This cross-sectional study involved analyzing the perspectives of experts from various regions in India regarding the use of teneligliptin as mono therapy or as an add-on therapy with other oral anti-diabetic drugs for the management of type 2 diabetes mellitus (T2DM) patients.
Results: The survey assessed the preferences of experts for several dipeptidyl-peptidase 4 (DPP-4) inhibitors namely sitagliptin, vildagliptin, linagliptin, teneligliptin, and saxagliptin. Approximately 40% of the 961 respondents reported that 11-20% of their diabetic patients received teneligliptin as mono therapy. Out of the 962 responses received, 43% reported a mean HbA1c reduction within the range of 0.75-1% when using teneligliptin. When teneligliptin was used in combination with metformin, around 50% of patients reported reaching the HbA1c target range of 26-50%. The most commonly reported benefits were improved renal safety (29.50%), reduced risk of hypoglycemia (34.71%), and avoidance of weight gain (33.08%). These findings provide significant evidence supporting the effectiveness and acceptability of teneligliptin as a DPP-4 inhibitor for the management of patients with T2DM. 
Conclusion: The study concluded that teneligliptin can be used as an effective treatment option either as mono therapy or in combination with other anti-diabetic medications to achieve glycemic control. By understanding the nuances of teneligliptin prescription practices, healthcare practitioners can tailor their approach to diagnosis, management, and treatment, ensuring that patients receive personalized care based on their specific clinical presentations and individual needs.